Surrozen, Inc. Common
Market Cap
230M
Short interest (Jul 15)
8.4%
Net Short (Jul 27 ): 0.2%
Borrow Fee
1.25%
Available Shares
200K
Price Chart
Company Overview
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.